Paeoniflorin relieves arterial stiffness induced by a high-fat/high-sugar diet by disrupting the YAP-PPM1B interaction

References

[1] Aggoun Y. Obesity, metabolic syndrome, and cardiovascular disease. Pediatr Res 2007;61:653–9.

[2] Tsai SS, Lin YS, Lin CP, et al. Metabolic syndrome-associated risk factors and high-sensitivity C-reactive protein independently predict arterial stiffness in 9903 subjects with and without chronic kidney disease. Medicine (Baltim) 2015;94:e1419.

[3] Nyati S, Schinske K, Ray D, et al. Molecular imaging of TGFbeta-induced Smad2/3 phosphorylation reveals a role for receptor tyrosine kinases in modulating TGFbeta signaling. Clin Cancer Res 2011;17:7424–39.

[4] Liu Y, Li M, Lv X, et al. Yes-associated protein targets the transforming growth factor beta pathway to mediate high-fat/high-sucrose diet-induced arterial stiffness. Circ Res 2022;130:851–67.

[5] Cao C, Zhao W, Chen X, et al. Deciphering the action mechanism of paeoniflorin in suppressing pancreatic cancer: a network pharmacology study and experimental validation. Front Pharmacol 2022;13:1032282.

[6] Yue M, Li S, Yan G, et al. Paeoniflorin inhibits cell growth and induces cell cycle arrest through inhibition of FoxM1 in colorectal cancer cells. Cell Cycle 2018;17:240–9.

[7] Keam SJ, Scott LJ, Curran MP. Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation. Drugs 2003;63:2521–54.

[8] Fisher MC, Alastruey-Izquierdo A, Berman J, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol 2022;20:557–71.

[9] Zhou YX, Gong XH, Zhang H, et al. A review on the pharmacokinetics of paeoniflorin and its anti-inflammatory and immunomodulatory effects. Biomed Pharmacother 2020;130:110505.

RIGHTS & PERMISSIONS

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.